United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction dated Friday, July 24th. The stock was sold at an average price of $531.74, for a total value of $5,051,530.00. Following the completion of the transaction, the chief executive officer owned 324,443 shares of the company’s stock, valued at approximately $172,519,320.82. This represents a 2.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
United Therapeutics Stock Down 0.8%
UTHR stock opened at $523.63 on Wednesday. The stock has a 50-day simple moving average of $546.23 and a two-hundred day simple moving average of $532.01. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $609.35. The firm has a market capitalization of $22.23 billion, a PE ratio of 19.33, a PEG ratio of 1.77 and a beta of 0.58.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. During the same period in the previous year, the company posted $6.63 earnings per share. The company’s quarterly revenue was down 1.6% compared to the same quarter last year. On average, equities research analysts anticipate that United Therapeutics Corporation will post 26.65 EPS for the current fiscal year.
Institutional Investors Weigh In On United Therapeutics
Analyst Ratings Changes
UTHR has been the subject of several analyst reports. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $575.00 to $735.00 in a report on Thursday, May 7th. Morgan Stanley set a $516.00 price target on shares of United Therapeutics in a report on Thursday, May 7th. Bank of America lowered their price objective on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Raymond James Financial started coverage on United Therapeutics in a research note on Friday, April 10th. They set an “outperform” rating and a $700.00 price objective for the company. Finally, JPMorgan Chase & Co. boosted their target price on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $648.33.
View Our Latest Stock Analysis on United Therapeutics
United Therapeutics Company Profile
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Featured Stories
- Five stocks we like better than United Therapeutics
- These 3 Stocks Have Soared in 2026—Can They Keep Climbing?
- Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story
- Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction
- Chips & Clips: Memory Tariffs Rewire Tech Supply Chains
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
